决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:Efficacy of kangfuxin liquid on radiotherapy-induced oral mucositis for patients with head and neck squamous cell carcinoma and its effect on salivary glands and immune function.
Efficacy of kangfuxin liquid on radiotherapy-induced oral mucositis for patients with head and neck squamous cell carcinoma and its effect on salivary glands and immune function.
康复新液可有效预防头颈部鳞状细胞癌患者放射性口腔黏膜炎的发生,减轻口腔黏膜反应和口腔疼痛,改善唾液腺功能,减轻炎症反应,促进细胞免疫功能,提高生活质量,改善预后。
观察康复新液对头颈部鳞状细胞癌患者放疗所致口腔黏膜炎的疗效及其对唾液腺和免疫功能的影响。
回顾性分析2019年1月至2021年6月在贵港市人民医院接受放疗的97例头颈部鳞状细胞癌患者,根据治疗方案不同分为对照组和试验组。两组接受相同的放射治疗。对照组(n=46)给予含硼砂的漱口水,试验组(n=51)给予康复新液治疗。我们观察两组在放疗前、放疗21 d和42 d后口腔黏膜炎和口腔疼痛的发生率及分级、唾液流率、唾液pH值、表皮生长因子(EGF)和淀粉酶水平、CD4 + /CD8 +、CD19 + /CD69 + 和自然杀伤(NK)细胞水平以及血清细胞因子(TGF-β1、IL-6和C反应蛋白(CRP))水平的变化。比较两组在放疗前和放疗42 d后的癌症患者生活质量测定量表-头颈癌(QLICP-HN)评分。
两组放疗前均未发现口腔黏膜炎或口腔疼痛。试验组放疗21 d和42 d后口腔黏膜炎和口腔疼痛的发生率与对照组无显著差异(均P>0.05)。试验组放疗21 d和42 d后口腔黏膜炎和口腔疼痛的等级均低于对照组(均P<0.05)。试验组唾液流率、唾液pH、EGF和淀粉酶水平以及CD4 + /CD8 +、CD19 + /CD69 + 和NK细胞水平均较高。试验组放疗21 d和42 d后血清TGF-β1、IL-6和CRP水平低于对照组(均P<0.05)。试验组放疗42 d后QLICP-HN量表各条目评分及总分均高于对照组(均P<0.05)。
OBJECTIVE: To observe the efficacy of Kangfuxin liquid on radiotherapy-induced oral mucositis for patients with head and neck squamous cell carcinoma and its effects on salivary glands and immune function. METHODS: A total of 97 patients with head and neck squamous cell carcinoma receiving radiotherapy in Guigang City People's Hospital from January 2019 to June 2021 were retrospectively analyzed and divided into a control group and a test group according to different treatment plans. The two groups received the same radiation therapy. Patients in the control group (n=46) were given borax-containing gargles, while those in the test group (n=51) were treated with Kangfuxin liquid. We observed the incidences and grades of oral mucositis and oral pain, changes in saliva flow rate, pH of saliva, levels of epidermal growth factor (EGF) and amylase, levels of CD4 + /CD8 + , CD19 + /CD69 + and natural killer (NK) cells, and serum cytokine (TGF-β1, IL-6 and C-reactive protein (CRP)) levels in the two groups before radiotherapy, and after 21 d and 42 d of radiotherapy. Quality of Life Instruments for Cancer Patients-Head and Neck Cancer (QLICP-HN) scores were compared in both groups before radiotherapy, and after 42 d of radiotherapy. RESULTS: No oral mucositis or oral pain was found before radiotherapy in both groups. The incidences of oral mucositis and oral pain after 21 d and 42 d of radiotherapy in the test group were not significantly different from those in the control group (all P>0.05). The grades of oral mucositis and oral pain in the test group after 21 d and 42 d of radiotherapy were lower than those in the control group (all P<0.05). The test group had higher saliva flow rate, pH of saliva, levels of EGF and amylase, and levels of CD4 + /CD8 + , CD19 + /CD69 + and NK cells. The test group had lower serum levels of TGF-β1, IL-6, and CRP than the control group after 21 d and 42 d of radiotherapy (all P<0.05). The scores of each item of the QLICP-HN scale and total scores in the test group were higher than those of the control group after 42 d of radiotherapy (all P<0.05). CONCLUSION: Kangfuxin liquid effectively prevents the occurrence of radiotherapy-induced oral mucositis for patients with head and neck squamous cell carcinoma, reduces oral mucosal reactions and oral pain, improves salivary gland function, reduces inflammatory response, promotes cellular immune function, improves quality of life, and improves prognosis.
MEMBER ACCOUNT
登录成功会直接打开下一页。